In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Overview

The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 2009

Arms, Groups and Cohorts

  • 1
    • Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.

Clinical Trial Outcome Measures

Primary Measures

  • Decrease in blood pressure
    • Time Frame: once after 4 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least <140/90 mgHg and the doctor has decided – Signed and dated Patient Informed Consent (ICF) Exclusion Criteria:

  • Hypersensitivity to the active substance or to any of the excipients of Atacand.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Janis Dobelis, AstraZeneca MC Latvia
  • Overall Official(s)
    • Agrita Hartmane, Study Director, AstraZeneca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.